Behind the Paper
The real stories behind the latest research papers, from conception to publication, the highs and the lows
Self-powered and speed-adjustable sensor for abyssal ocean current measurements based on triboelectric nanogenerators
An ultra-compact deep-sea current sensor utilizing triboelectric nanogenerator technology is developed.Measurements conducted at a depth of 4,531 meters demonstrated that the instrument can accurately measure a wide range of flow velocities,from 0.02 m/s to 6.69 m/s,with the highest sensitivity.
Introducing scCross: a deep generative model for unifying single-cell multi-omics with seamless integration, cross-modal generation, and in-silico exploration
Introducing scCross: a deep generative model for integrating single-cell multi-omics with seamless cross-modal generation and exploration. scCross enables efficient cross-modal data generation, multi-omic data simulation, and in-silico perturbations within and across different modalities.
Unveiling the association between HMG-CoA reductase inhibitors and bladder cancer: A comprehensive analysis using Mendelian randomization, animal models, and transcriptomics
Our study identifies HMG-CoA reductase (HMGCR) inhibitors, particularly simvastatin, as potential agents for reducing bladder cancer (BLCA) risk, and provides potential insight for clinical practice for BLCA treatment or adjuvant therapy.
Flexibility meets quality and scale
Finding solutions to all of these challenges was a major bottleneck for the burgeoning field of single-cell mass spectrometry proteomics.
Filling the spectral gap of persistent luminescence
By engineering sub-bandgap donor-acceptor states within a series of single-phase Ca(Sr)ZnOS crystals, the persistent luminescence emission peak can now be quasi-linearly tuned across a broad wavelength range (500–630 nm) as a function of Sr/Ca ratio.
PTMGPT2: An Interpretable Protein Language Model for Enhanced Post-Translational Modification Prediction
PTMGPT2 uses GPT-based architecture and prompt-based fine-tuning to predict post-translational modifications. It outperforms existing methods across 19 PTM types, offering interpretability and mutation analysis. This advances the understanding of protein function and disease research.
Mutation in Bruton Tyrosine Kinase (BTK) A428D Confers Resistance To BTK-Degrader Therapy In Chronic Lymphocytic Leukemia
Drugs that target BTK for proteasomal degradation, so-call BTK degraders, are presumed able to mitigate the risk of drug resistance due to BTK mutations. In Leukemia 38:1818 (2024), Kipps and colleagues describe a patient who developed resistance to the BTK-degrader BGB-16673 via a mutation in BTK.
